+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 133174-15-9
133174-15-9,MFCD00151943
Catalog No.:AA0014AS

133174-15-9 | Fmoc-Cit-OH

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5g
98%
in stock  
$7.00   $5.00
- +
10g
98%
in stock  
$13.00   $9.00
- +
25g
98%
in stock  
$27.00   $19.00
- +
100g
98%
in stock  
$94.00   $66.00
- +
500g
98%
in stock  
$415.00   $291.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA0014AS
Chemical Name:
Fmoc-Cit-OH
CAS Number:
133174-15-9
Molecular Formula:
C21H23N3O5
Molecular Weight:
397.4244
MDL Number:
MFCD00151943
SMILES:
NC(=O)NCCC[C@@H](C(=O)O)NC(=O)OCC1c2ccccc2c2c1cccc2
Properties
Properties
 
Form:
Solid  
MP:
168-175 °C  
Refractive Index:
-10 ° (C=1, DMF)  
Storage:
Keep in dry area;Room Temperature;  

Computed Properties
 
Complexity:
577  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
4  
Rotatable Bond Count:
9  
XLogP3:
2.1  

Downstream Synthesis Route
623-04-1   
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoicacid 
  870487-04-0 

[1]CurrentPatentAssignee:HelmholtzAssociation-WO2019/30284,2019,A1Locationinpatent:Paragraph00171;00172

[2]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-WO2005/112919,2005,A2Locationinpatent:Page/Pagecolumn123-124

[3]CurrentPatentAssignee:SYNAFFIXBV-WO2014/65661,2014,A1Locationinpatent:Page/Pagecolumn75

[4]CurrentPatentAssignee:ASTRAZENECAPLC;ROCHEHOLDINGAG-WO2015/95124,2015,A1Locationinpatent:Page/Pagecolumn18

[5]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2016/90038,2016,A1Locationinpatent:Page/Pagecolumn124-125

[6]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2016/90040,2016,A1Locationinpatent:Page/Pagecolumn90;91

[7]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2016/205176,2016,A1Locationinpatent:Paragraph00342

[8]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2017/214024,2017,A1Locationinpatent:Page/Pagecolumn81;82;83

[9]Märcher,Anders;Nijenhuis,MinkeA.D.;Gothelf,KurtV.[AngewandteChemie-InternationalEdition,2021,vol.60,#40,p.21691-21696][Angew.Chem.,2021,vol.133,#40,p.21859-21864]

[10]CurrentPatentAssignee:BAYLORUNIVERSITY-WO2017/66668,2017,A1Locationinpatent:Paragraph000159

[11]Mondal,Deboprosad;Ford,Jacob;Pinney,KevinG.[TetrahedronLetters,2018,vol.59,#40,p.3594-3599]

[12]CurrentPatentAssignee:ARROWHEADRESEARCHCORP-WO2015/21092,2015,A1Locationinpatent:Page/Pagecolumn40

[13]CurrentPatentAssignee:ELUCIDAONCOLOGY-WO2022/93800,2022,A2Locationinpatent:Paragraph00440-00441;00607-00608

[14]CurrentPatentAssignee:ELUCIDAONCOLOGY-WO2022/93800,2022,A2Locationinpatent:Paragraph00440-00441;00607-00608

[15]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2015/95223,2015,A2Locationinpatent:Page/Pagecolumn67;68;69

[16]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2015/95227,2015,A2Locationinpatent:Page/Pagecolumn261;263

[17]CurrentPatentAssignee:WUXIAPPTECCO.,LTD.-WO2016/8112,2016,A1Locationinpatent:Page/Pagecolumn32

[18]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2016/90050,2016,A1Locationinpatent:Page/Pagecolumn63

[19]CurrentPatentAssignee:ABBVIEINC-WO2016/94509,2016,A1Locationinpatent:Paragraph0001026

[20]CurrentPatentAssignee:ABBVIEINC-WO2017/214462,2017,A2Locationinpatent:Page/Pagecolumn595

[21]CurrentPatentAssignee:ABBVIEINC-US2017/355769,2017,A1Locationinpatent:Paragraph2005

[22]Wei,Binqing;Gunzner-Toste,Janet;Yao,Hui;Wang,Tao;Wang,Jing;Xu,Zijin;Chen,Jinhua;Wai,John;Nonomiya,Jim;Tsai,SiaoPing;Chuh,Josefa;Kozak,KatherineR.;Liu,Yichin;Yu,Shang-Fan;Lau,Jeff;Li,Guangmin;Phillips,GailD.;Leipold,Doug;Kamath,Amrita;Su,Dian;Xu,Keyang;Eigenbrot,Charles;Steinbacher,Stefan;Ohri,Rachana;Raab,Helga;Staben,LeannaR.;Zhao,Guiling;Flygare,JohnA.;Pillow,ThomasH.;Verma,Vishal;Masterson,LukeA.;Howard,PhilipW.;Safina,Brian[JournalofMedicinalChemistry,2018,vol.61,#3,p.989-1000]

[23]CurrentPatentAssignee:ABBVIEINC-WO2017/214456,2017,A1Locationinpatent:Page/Pagecolumn293

[24]CurrentPatentAssignee:ABBVIEINC-US2019/153107,2019,A1Locationinpatent:Paragraph0928

[25]CurrentPatentAssignee:COMMONWEALTHSCIENTIFICANDINDUSTRIALRESEARCHORGANISATION-CN110366430,2019,ALocationinpatent:Paragraph0487

[26]CurrentPatentAssignee:SICHUANKELUNPHARMACEUTICALCOMPANYLIMITED-US2020/347075,2020,A1Locationinpatent:Paragraph0321-0322

[1]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2010/145036,2010,A1Locationinpatent:Page/Pagecolumn87-88

[2]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-WO2008/103693,2008,A2Locationinpatent:Page/Pagecolumn86;89;105;109

[1]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2010/145036,2010,A1Locationinpatent:Page/Pagecolumn88

CASUnavailable 
  133174-15-9   
CASUnavailable 

[1]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-WO2013/122823,2013,A1Locationinpatent:Paragraph00164

[1]CurrentPatentAssignee:ROCHEHOLDINGAG;THEUNIVERSITYOFAUCKLAND-WO2015/23355,2015,A1Locationinpatent:Page/Pagecolumn107;108

Literature

Title: The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease.

Journal: Bioorganic & medicinal chemistry 19970701

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 133174-15-9
101555-63-9

101555-63-9

 101555-62-8

101555-62-8

 114360-54-2

114360-54-2

 1172579-62-2

1172579-62-2

 117322-30-2

117322-30-2

 1191429-20-5

1191429-20-5
Building Blocks
More >
Tags:133174-15-9 Molecular Formula|133174-15-9 MDL|133174-15-9 SMILES|133174-15-9 Fmoc-Cit-OH